04028nam 22004453 450 991081350440332120230629231822.09789280533606(electronic bk.)9789280533590(MiAaPQ)EBC7113890(Au-PeEL)EBL7113890(CKB)25165210100041(OCoLC)1348480949(EXLCZ)992516521010004120221019d2022 uy 0engurcnu||||||||txtrdacontentcrdamediacrrdacarrierCOVID-19-related vaccines and therapeutics Preliminary insights on related patenting activity during the pandemicGeneva :World Intellectual Property Organization,2022.©2022.1 online resource (83 pages)Print version: Staff, World Intellectual Property Organization COVID-19-related vaccines and therapeutics Geneva : World Intellectual Property Organization,c2022 9789280533590 Intro -- _Hlk93048502 -- Acknowledgements -- Key findings -- Introduction -- Background - biology of COVID-19 -- Overview of patenting activity related to COVID-19 -- Patent filings during 2020-2021 -- Filing and publication of COVID-19-related patent applications over time -- COVID-19-related vaccine and therapeutic patent applicant profiles -- Research collaboration and IP strategies related to technologies important to COVID-19 vaccines and therapeutics -- Disclosure of sequences within patent documents -- COVID-19 vaccines -- Background - vaccine platforms -- Conventional vaccine platforms -- Novel vaccine platforms -- Patent and vaccine distribution by vaccine platform and published applicant location -- Speed of vaccine development -- COVID-19 vaccine patent landscape -- Core vaccine technologies, collaboration and licensing -- Analysis of WHO data on COVID-19 vaccines -- Timelines on key technologies for COVID-19 vaccine development -- Technologies relevant to mRNA vaccine -- Timeline details for adenovirus vaccine development -- Timeline details for vaccine adjuvant development -- COVID-19 therapeutics -- Background -- Analysis of COVID-19 therapeutics-related patent applications by substances type -- Top locations of patent applicants for COVID-19 therapeutics and their filing strategies -- Highlights of patent filings related to COVID-19 therapeutic development -- Patent filings related to development of small-molecule drugs for COVID-19 -- Patent filings related to the development of biologics for COVID-19 -- Patents related to antibodies for COVID-19 treatment -- Peptide and protein therapies -- Nucleic-acid-based therapies -- Aptamer-mediated therapy -- Cell-based therapies -- Other biologic-based therapies -- Analysis of COVID-19 therapeutics in clinical trials.Analysis of COVID-19 therapeutics data in the Milken Institute and Regulatory Affairs Professionals Society (RAPS) tracker data -- Distribution of COVID-19 drug candidates across small molecules and biologics, repurposed drugs and de novo synthesized drugs -- Classification of COVID-19 drug candidates in clinical trials by molecular nature and function -- Feature summary of examples of anti-COVID-19 drug candidates in clinical trials -- Perspectives -- Annex -- Data sources and methods -- Tables of vaccine types and candidates currently in clinical trials -- Examples of partial, early disclosure observed at the Israeli, U.K. and Singapore patent offices -- Glossary -- References -- Further reading.COVID-19 (Disease)PatentsPatents (International law)COVID-19 (Disease).Patents.Patents (International law).Staff World Intellectual Property Organization1648146MiAaPQMiAaPQMiAaPQ9910813504403321COVID-19-related vaccines and therapeutics4082899UNINA